First-pass extracted concept

CRISPR-based gene and cell therapies

Candidate: concept label1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This label refers to therapeutic use of CRISPR technologies in gene and cell therapy settings. The abstract frames these approaches as moving from experimental use toward clinical application.

Source 1DOI PubMed

What problem it solves

The review presents CRISPR-based therapies as expanding the therapeutic landscape beyond traditional gene knockout approaches.

Source 1DOI PubMed

What it does not solve

The abstract explicitly notes unresolved delivery, long-term safety, immune response, and editing specificity issues.

Source 1DOI PubMed

Alternatives

The abstract contrasts newer CRISPR modalities with traditional gene knockout approaches.

Source 1DOI PubMed

Evidence Snippets

CRISPR-based gene and cell therapies are rapidly transitioning from experimental platforms to clinical reality

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1clinical examplesupports2026Source 1DOI PubMed

The recent approval of CRISPR-derived treatments for beta-hemoglobinopathies exemplifies the clinical transition of CRISPR-based therapies.

Claim 2translational statussupports2026Source 1DOI PubMed

CRISPR-based gene and cell therapies are rapidly transitioning from experimental platforms to clinical reality.

Claim 3translation considerationsupports2026Source 1DOI PubMed

Delivery challenges, long-term safety, immune responses, and editing specificity are critical considerations for safe and effective integration of CRISPR technologies into medicine.